Managing GA in clinical practice: new challenges, new models
With the new treatments for GA, it is important to re-think the management of patients looking at th
The new era in the management of patients with geographic atrophy
Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy appr
Euretina 2023 – Controversies and future trends in intravitreal therapies
IVEG instructional course – Euretina 2023Take-home messagesIn this video, the best of our
IVEG Course: Controversies and Future Trends in Intravitreal Therapies
On 8 October at the Euretina 2023 congress in Amsterdam, international TLs will discuss controversie
Home monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r
High-dose Aflibercept: the PHOTON and PULSAR trials
Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and th
FDA approves high-dose Eylea for the treatment of wAMD, DME and diabetic retinopathy
The U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) 8mg injection for th
What is the current situation of ophthalmology in Ukraine?
Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.
FDA CRL puts temporarily on hold the approval of high-dose Eylea
Regeneron announced that the FDA issued a CRL to the approval application for aflibercept 8 mg for t
Office, ambulatory surgery room or operating theatre?
A study reviews evidence and provides recommendations for the ideal setting of intravitreal injectio
PHOTON and PULSAR studies: an overview of the results
Professor Jean-François Korobelnik reviews the results at one year of the PHOTON and PULSAR studies
Study revamps concerns about nonpowder toy gun as a cause of pediatric eye injuries
A study performed at the Rothschild Foundation Hospital in Paris showed that pediatric eye injuries
The importance of diabetic eye screening
Diabetic Eye Screening campaigns have a key role in the prevention and treatment of diabetic related
No association between RVO and mRNA COVID-19 vaccination, study shows
A retrospective, population-based study showed that there is no association between RVO and mRNA COV
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
New treatment for Retinitis Pigmentosa shows positive results
A new optogenetic therapy is on the horizon
Aviceda submits Investigational New Drug application for AVD-104 for geographic atrophy
Aviceda Therapeutics submitted Investigational New Drug (IND) and Fast Trac
Durability and safety of new treatments for nAMD
Retina thought leaders give opinions on new treatments for nAMD
First treatment for Geographic Atrophy (GA) approved by FDA
On February 17, the FDA approved SYFOVRE™ (pegcetacoplan, Apellis Pharmac
Aflibercept 8 mg accepted by FDA for priority review for the treatment of wet AMD and DME
FDA has accepted for priority review the Biologics License Application (BLA
A team approach to diabetes-related eye disease
To tackle diabetes-related eye diseases through a multidisciplinary team approach.
Treat & Extend in ME secondary to CRVO
In the CENTERA study, significant functional and anatomic improvements were
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
The Debate on Fluid Tolerance
What do the studies show? What do the experts think?
What is on the Horizon? A Symposium on the future of ophthalmology at Euretina 2021
Home monitoring, intravitreal treatments, gene therapy, AI. The future of ophthalmology through the
A video journey in the “new normal” of retina practices
Euretina 2021 Virtual Congress
Timely detection of wet AMD with remote home screening
Data from a retrospective real world study highlights low incidence of proactive treatment of nAMD
Remote monitoring in the management of retinal disease
Latest news
Managing GA in clinical practice: new challenges, new models
With the new treatments for GA, it is important to re-think the management of patients looking at the already established clinical practice.
LEARN MOREThe new era in the management of patients with geographic atrophy
Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy approved by the FDA.
LEARN MOREIVEG Course: Controversies and Future Trends in Intravitreal Therapies
On 8 October at the Euretina 2023 congress in Amsterdam, international TLs will discuss controversies and future trends in IV therapies
LEARN MOREHome monitoring
Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her research leadership played a crucial role.
LEARN MOREHigh-dose Aflibercept: the PHOTON and PULSAR trials
Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and the two pivotal PHOTON and PULSAR trials
LEARN MOREFDA approves high-dose Eylea for the treatment of wAMD, DME and diabetic retinopathy
The U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) 8mg injection for the treatment of wet AMD, DME and diabetic retinopathy (DR).
LEARN MOREWhat is the current situation of ophthalmology in Ukraine?
Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.
LEARN MOREFDA CRL puts temporarily on hold the approval of high-dose Eylea
Regeneron announced that the FDA issued a CRL to the approval application for aflibercept 8 mg for the treatment of wAMD, DME and DR.
LEARN MOREOffice, ambulatory surgery room or operating theatre?
A study reviews evidence and provides recommendations for the ideal setting of intravitreal injections.
LEARN MOREAbout us
a panel of top-tier international vitreoretinal surgeons
The experience shared by this group of professionals is aligned with their mission to promote and provide best practice recommendations
Only modern and best equipment advanced medical technologies and innovative diagnosis and treatment methods and technology.
Our organization has received a financial education grant from Bayer. Bayer has had no influence on this website content.